Search clinical trials for: Efavaleukin Alfa

Total 3066 results

Organon and Co

Completed

A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788) (Realize)

In Vitro Fertilization
The Hospital for Sick Children

Completed

Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure

Kidney Failure, Chronic

Canada
Janssen-Cilag B.V.

Completed

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Anemia | HIV
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Stomach Neoplasms | Rectal Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.

Anemia | Blood Transfusion | Orthopedic Procedures
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Cardiovascular Surgical Procedure | Blood Transfusion, Autologous
Janssen-Ortho Inc., Canada

Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

Anemia
Janssen Cilag S.A.S.

Terminated

Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

Anemia | Renal Failure, Chronic Renal Failure
Janssen Pharmaceutica N.V., Belgium

Completed

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Chronic Renal Failure
Amgen

Completed

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

Chronic Kidney Disease
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy

Anemia
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Hepatitis B

China
Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Cervical Cancer | Ovarian Cancer

China
Westfälische Wilhelms-Universität Münster
Chiesi GmbH

Recruiting

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa (GoPEG)

Fabry Disease

Germany
Taipei Veterans General Hospital, Taiwan

Not yet recruiting

Higher Dose of Alglucosidase Alpha for Pompe Disease

Glycogen Storage Disease Type II
The University of Hong Kong
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Nasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing Carinoma

Hong Kong
University of Turin, Italy

Completed

Prospective Randomized Trial Comparing Corifollitropin-alfa Late Start vs. Corifollitropin-alfa Standard Start in Expected Poor, Normal and High-responders Undergoing IVF

Fertility Disorders

Italy
University Hospital Tuebingen
Joachim Riethmueller, Dr. med.

Unknown

Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa

Long Term Ventilation

Germany
Sanofi

Recruiting

Avalglucosidase Alfa Pregnancy Study

Pregnancy | Pompe Disease

United States
PharmaEssentia

Recruiting

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Polycythemia Vera

United States, Canada
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study (SIMPLIFY-DN)

Cystic Fibrosis

United States
Genzyme, a Sanofi Company

Approved for marketing

Alglucosidase Alfa Temporary Access Program (ATAP)

Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)

United States
Kyowa Kirin Co., Ltd.

Completed

A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients

Anemia

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Critical Illness | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Cancer | Anemia

United States
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Carcinoma | Prostate
Amgen

Completed

Heart Failure and Anemia

Heart Failure | Anemia
Amgen

Completed

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Lymphoma | Breast Neoplasms | Lung Neoplasms | Multiple Myeloma | Chronic Lymphocytic Leukemia
Amgen

Completed

Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease

Anemia | Kidney Disease
AM-Pharma

Completed

Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia

Hypophosphatasia

Germany
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Extension Study of PRX-102 for up to 60 Months

Fabry Disease

United States, Spain, United Kingdom, Paraguay
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Lymphoma | Leukemia | Breast Cancer | Chronic Myeloproliferative Disorders | Anemia | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Amgen

Completed

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Kyowa Kirin Co., Ltd.

Completed

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Anemia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Anemia

United States
Amgen

Completed

Fixed Dose NESP Study in Subjects With CRI

Pre-Dialysis
Amgen

Completed

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Anemia
Amgen

Completed

Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects

Anemia
Shanghai Zhongshan Hospital

Not yet recruiting

Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

Myasthenia Gravis
Denali Therapeutics Inc.

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Mucopolysaccharidosis II

United States, Canada, Belgium, Czechia, Netherlands
Denali Therapeutics Inc.

Active, not recruiting

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Mucopolysaccharidosis II

United States, Netherlands, Canada, United Kingdom

3

Subscribe